Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.
Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session ...
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is issuing a voluntary recall of one lot of Veklury® (remdesivir) for Injection 100 mg/vial, to the consumer level. Gilead received a customer c ...
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
Zacks.com on MSN5d
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's WhyThe latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.
By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V ...
NORTHAMPTON, MA / ACCESSWIRE / September 18, 2024 / Gilead SciencesJackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the directio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback